{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:10:28Z","timestamp":1767773428489},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1007\/s12149-007-0075-2","type":"journal-article","created":{"date-parts":[[2008,2,4]],"date-time":"2008-02-04T05:28:40Z","timestamp":1202102920000},"page":"73-77","source":"Crossref","is-referenced-by-count":11,"title":["Distinctive FDG and FES accumulation pattern of two tamoxifen-treated patients with endometrial hyperplasia"],"prefix":"10.1007","volume":"22","author":[{"given":"Tetsuya","family":"Tsujikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehiko","family":"Okazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuro","family":"Tsuchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhisa","family":"Fujibayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"75_CR1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X","volume":"56","author":"R.J. Kurman","year":"1985","unstructured":"Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia: a long-term study of \u201cuntreated\u201d hyperplasia in 170 patients. Cancer 1985;56:403\u2013412.","journal-title":"Cancer"},{"key":"75_CR2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ygyno.2004.12.007","volume":"97","author":"L.J. Havrilesky","year":"2005","unstructured":"Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol 2005;97:183\u2013191.","journal-title":"Gynecol Oncol"},{"key":"75_CR3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1148\/radiology.169.1.3262228","volume":"169","author":"M.A. Mintun","year":"1988","unstructured":"Mintun MA, Welch MJ, Siegel BA, Mathias CJ, Brodack JW, McGuire AH, et al. Breast cancer: PET imaging of estrogen receptors. Radiology 1988;169:45\u201348.","journal-title":"Radiology"},{"key":"75_CR4","first-page":"1526","volume":"32","author":"A.H. McGuire","year":"1991","unstructured":"McGuire AH, Dehdashti F, Siegel BA, Lyss AP, Brodack JW, Mathias CJ, et al. Positron tomographic assessment of 16\u03b1-[18F]fluoro-17\u03b2-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991;32:1526\u20131531.","journal-title":"J Nucl Med"},{"key":"75_CR5","first-page":"1766","volume":"36","author":"F. Dehdashti","year":"1995","unstructured":"Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselman MJ, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDGPET and in vitro receptor assays. J Nucl Med 1995;36:1766\u20131774.","journal-title":"J Nucl Med"},{"key":"75_CR6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s002590050359","volume":"26","author":"F. Dehdashti","year":"1999","unstructured":"Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of \u201cmetabolic flare\u201d to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999;26:51\u201356.","journal-title":"Eur J Nucl Med"},{"key":"75_CR7","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1200\/JCO.2001.19.11.2797","volume":"19","author":"J.E. Mortimer","year":"2001","unstructured":"Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001;19:2797\u20132803.","journal-title":"J Clin Oncol"},{"key":"75_CR8","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1200\/JCO.2005.04.3810","volume":"24","author":"H.M. Linden","year":"2006","unstructured":"Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 2006;24:2793\u20132799.","journal-title":"J Clin Oncol"},{"issue":"Suppl2","key":"75_CR9","first-page":"386P","volume":"48","author":"T. Tsujikawa","year":"2007","unstructured":"Tsujikawa T, Okazawa H, Yoshida Y, Mori T, Kobayashi M, Tsuchida T, et al. Differential diagnosis of endometrial hyperplasia and cancer using combined 18F-FES and 18F-FDG PET (abstract). J Nucl Med 2007;48Suppl 2:386P.","journal-title":"J Nucl Med"},{"key":"75_CR10","first-page":"1212","volume":"25","author":"D.O. Kiesewetter","year":"1984","unstructured":"Kiesewetter DO, Kilbourn MR, Landvatter SW, Heiman DF, Katzenellenbogen JA, Welch MJ. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med 1984;25:1212\u20131221.","journal-title":"J Nucl Med"},{"key":"75_CR11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.nucmedbio.2005.11.002","volume":"33","author":"T. Mori","year":"2006","unstructured":"Mori T, Kasamatsu S, Mosdzianowski C, Welch MJ, Yonekura Y, Fujibayashi Y. Automatic synthesis of 16\u03b1-[18F]fluoro-17\u03b2-estradiol using a cassette-type [18F]fluorodeoxyglucose synthesizer. Nucl Med Biol 2006;33:281\u2013286.","journal-title":"Nucl Med Biol"},{"key":"75_CR12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1525-1438.2005.15321.x","volume":"15","author":"K. Hu","year":"2005","unstructured":"Hu K, Zhong G, He F. Expression of estrogen receptors ER\u03b1 and ER\u03b2 in endometrial hyperplasia and adenocarcinoma. Int J Gynecol Cancer 2005;15:537\u2013541.","journal-title":"Int J Gynecol Cancer"},{"key":"75_CR13","first-page":"237","volume":"69","author":"M.A. Killackey","year":"1985","unstructured":"Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985;69:237\u2013238.","journal-title":"Cancer Treat Rep"},{"key":"75_CR14","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.1021\/jm050121f","volume":"48","author":"J. Yoo","year":"2005","unstructured":"Yoo J, Dence CS, Sharp TL, Katzenellenbogen JA, Welch MJ. Synthesis of an estrogen receptor \u03b2-selective radioligand: 5-[18F]fluoro-(2R*,3S*)-2,3-bis(4-hydroxyphehyl) pentanenitrile and comparison of in vivo distribution with 16\u03b1-[18F]fluoro-17\u03b2-estradiol. J Med Chem 2005;48:6366\u20136378.","journal-title":"J Med Chem"},{"key":"75_CR15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.nucmedbio.2006.12.003","volume":"34","author":"T. Tsuchida","year":"2007","unstructured":"Tsuchida T, Okazawa H, Mori T, Kobayashi M, Yoshida Y, Fujibayashi Y, et al. In vivo imaging of estrogen receptor concentration in the endometrium and myometrium using FES PET: influence of menstrual cycle and endogenous estrogen level. Nucl Med Biol 2007;34:205\u2013210.","journal-title":"Nucl Med Biol"},{"key":"75_CR16","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1002\/1097-0142(20000615)88:12<2774::AID-CNCR16>3.0.CO;2-I","volume":"88","author":"B.Y. Wang","year":"2000","unstructured":"Wang BY, Kalir T, Sabo E, Sherman DE, Cohen C, Burstein DE. Immunohistochemical staining of GLUT1 in benign, hyperplastic, and malignant endometrial epithelia. Cancer 2000;88:2774\u20132781.","journal-title":"Cancer"},{"key":"75_CR17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1006\/gyno.1997.4831","volume":"67","author":"I. Cohen","year":"1997","unstructured":"Cohen I, Beyth Y, Altaras MM, Shapira J, Tepper R, Cardoba M, et al. Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies. Gynecol Oncol 1997;67:8\u201315.","journal-title":"Gynecol Oncol"},{"key":"75_CR18","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ygyno.2003.10.040","volume":"92","author":"J.L. Wilder","year":"2004","unstructured":"Wilder JL, Shajahan S, Khattar NH, Wilder DM, Yin J, Rushing RS, et al. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-\u03b1, estrogen-\u03b2 and progesterone: a case controlled study. Gynecol Oncol 2004;92:553\u2013558.","journal-title":"Gynecol Oncol"},{"key":"75_CR19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0163-7258(84)90043-3","volume":"25","author":"B.J. Furr","year":"1984","unstructured":"Furr BJ, Nicholson RI. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984;25:127\u2013205.","journal-title":"Pharmacol Ther"},{"key":"75_CR20","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/1097-0142(19810815)48:4<876::AID-CNCR2820480403>3.0.CO;2-Q","volume":"48","author":"C. Fabian","year":"1981","unstructured":"Fabian C, Sternson L, El-Serafi M, Cain L, Hearne E. Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data. Cancer 1981;48:876\u2013882.","journal-title":"Cancer"},{"key":"75_CR21","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ygyno.2006.10.024","volume":"104","author":"Y. Yoshida","year":"2007","unstructured":"Yoshida Y, Kurokawa T, Sawamura Y, Shinagawa A, Okazawa H, Fujibayashi Y, et al. The positron emission tomography with F18 17\u03b2-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer. Gynecol Oncol 2007;104:764\u2013766.","journal-title":"Gynecol Oncol"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-007-0075-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12149-007-0075-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-007-0075-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T04:41:45Z","timestamp":1559450505000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12149-007-0075-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["75"],"URL":"https:\/\/doi.org\/10.1007\/s12149-007-0075-2","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}